Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2013-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.12073PMID 23356556
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

  2013cited by this paper
• Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

  2012cited by this paper
• Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

  2012influential reference
• Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

  2012cited by this paper
• Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

  2011cited by this paper
• Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

  2011cited by this paper
• Role of Chronic and Acute Hyperglycemia in the Development of Diabetes Complications

  2011cited by this paper
• Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

  2011cited by this paper
• Standards of Medical Care in Diabetes—2011

  2011cited by this paper
• Management of diabetes across the course of disease: minimizing obesity-associated complications

  2011cited by this paper
• Dapagliflozin: more than just another oral glucose-lowering agent?

  2010cited by this paper
• Defining and achieving treatment success in patients with type 2 diabetes mellitus.

  2010cited by this paper
• Emerging treatment options for type 2 diabetes.

  2010cited by this paper
• Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

  2010cited by this paper
• Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.

  2010cited by this paper
• Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

  2010cited by this paper
• Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

  2009cited by this paper
• Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

  2009cited by this paper
• A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers

  2009cited by this paper
• Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects

  2009cited by this paper
• Therapeutic targets to reduce cardiovascular disease in type 2 diabetes

  2009cited by this paper
• Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

  2009cited by this paper
• Effect of a multifactorial intervention on mortality in type 2 diabetes.

  2008cited by this paper
• Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

  2008cited by this paper
• Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.

  2008cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper

• Investigation of Cytotoxic Effects of Empagliflozin on Caco-2, LNCaP and A2780 Human Cancer Cell Lines

  2026cites this paper
• Green analytical chemistry meets pharmaceutical analysis: Optimization and validation of a TLC-densitometric method for simultaneous determination of linagliptin and empagliflozin after eco-friendly extraction

  2026cites this paper
• Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open‐Label, Crossover Study in Fasting Healthy Volunteers

  2025cites this paper
• Pharmacokinetic Comparison and Bioequivalence Evaluation of Two Empagliflozin/Metformin Fixed-Dose Combination Tablets in Healthy Subjects under Fed Conditions

  2025cites this paper
• Pharmacological modulation of the diabetic gut microbiome with gliflozin drugs:new insights for therapeutic targeting

  2025cites this paper
• Head-to-Head in Heart Failure: Comparative Insights on Empagliflozin and Dapagliflozin

  2025cites this paper
• The Role of Insulin Resistance in Cardiorenal Metabolic Syndrome.

  2025cites this paper
• Comparative Effects of Empagliflozin and Dapagliflozin in Stable Chronic Heart Failure　― A Prospective Crossover Study ―

  2025cites this paper
• Protective effects of empagliflozin against NMDA-induced excitotoxicity in the rat retina.

  2025cites this paper
• Effects of empagliflozin and its combination with docetaxel on LNCaP and DU- 145 prostate cancer cell lines: cytotoxicity and molecular pathway analysis

  2025influential citation
• TLR-4/Notch1/NF-κB pathway modulation by dapagliflozin: a novel mechanism for neuroprotection in hepatic encephalopathy

  2025cites this paper
• Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2

  2024influential citation
• Novel Potential Drug Interactions with Bisoprolol in Hospitalized Acute Coronary Syndrome Patients

  2024cites this paper
• Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview of Its Chemistry, Pharmacology, and Toxicology.

  2024cites this paper
• Novel Therapeutic Agents for Cardiometabolic Risk Mitigation in Heart Transplant Recipients.

  2024cites this paper
• Mechanistic Modeling of Empagliflozin: Predicting Pharmacokinetics, Urinary Glucose Excretion, and Investigating Compensatory Role of SGLT1 in Renal Glucose Reabsorption

  2024cites this paper
• Epidemiology of Heart Failure and the Discovery of the Cardioprotective Effects of SGLT2 Inhibitors.

  2024cites this paper
• Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases

  2024cites this paper
• Preliminary Study: Expulsive Effect of Empagliflozin on Small Lower Ureteric Stones in Type II Diabetic Patients

  2024cites this paper
• Transporter Proteins as Therapeutic Drug Targets—With a Focus on SGLT2 Inhibitors

  2024cites this paper
• Modern-Day Therapeutics and Ongoing Clinical Trials against Type 2 Diabetes Mellitus: A Narrative Review.

  2024cites this paper
• Empagliflozin demonstrates cytotoxicity and synergy with tamoxifen in ER-positive breast cancer cells: anti-proliferative and anti-survival effects

  2024influential citation
• Prevalence of Admission Hyponatremia in Patients With Diabetes Treated With and Without an SGLT2 inhibitor

  2023cites this paper
• Eco-friendly-assessed micellar-fluorimetric platform for concurrent analysis of empagliflozin and prucalopride succinate in biological fluids: Docking simulation.

  2023cites this paper
• Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy

  2023cites this paper
• Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?

  2023cites this paper
• Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.

  2023cites this paper
• Use of Oral Empagliflozin to Obtain Optimal Blood Sugar Levels for Conducting 18 F-FDG PET-CT in Patients with Hyperglycemia—A Pilot Study

  2023cites this paper
• Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice

  2023cites this paper
• SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus.

  2023cites this paper
• Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis

  2023cites this paper
• Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors - is renal hemodynamics the key point?

  2023cites this paper
• Dapagliflozin Ameliorates Neural Damage in the Heart and Kidney of Diabetic Mice

  2023cites this paper
• Safety of sodium‐glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta‐analysis

  2023cites this paper
• Comparative efficacy and safety of sodium–glucose cotransporter 2 inhibitors for renal outcomes in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis

  2023cites this paper
• Pharmacometrics enhanced Bayesian borrowing approach to improve clinical trial efficiency: Case of empagliflozin in type 2 diabetes

  2023cites this paper
• Development and validation of Empagliflozin and Linagliptin simultaneous estimation in rat plasma using freezing lipid precipitation and SCX-SPE assisted HPLC–MS/MS method and its application in pharmacokinetic studies

  2023cites this paper
• Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis

  2023cites this paper
• Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)

  2023cites this paper
• Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study

  2023cites this paper
• Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit

  2022cites this paper
• Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials

  2022cites this paper
• The effects of empagliflozin, dietary energy restriction, or both on appetite‐regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double‐blind, placebo‐controlled trial

  2022cites this paper
• Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes

  2022cites this paper
• Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis

  2022cites this paper
• Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors

  2022cites this paper
• Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis

  2022cites this paper
• SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review

  2022cites this paper
• Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis.

  2022cites this paper
• Effects of Methanol Extract of Gongronema latifolium Leaves on Glycaemic Responses to Carbohydrate Diets in Streptozotocin-induced Diabetic Rats

  2022cites this paper
• The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial

  2021cites this paper
• Sodium Glucose Cotransporter Inhibitors for the Treatment of Diabetes

  2021cites this paper
• Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus

  2021cites this paper
• Empagliflozin induced euglycemic diabetic ketoacidosis in a patient undergoing coronary artery bypass graft despite discontinuation of the drug 48 hours prior to the surgery.

  2021cites this paper
• A real-world clinical experience on the effectiveness of remogliflozin etabonate in management of Indian patients with type II diabetes mellitus

  2021cites this paper
• Do sodium‐glucose co‐transporter‐2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?

  2021cites this paper
• Potential mechanisms underlying the renoprotective effect of empagliflozin, a novel selective sodium glucose co-transporter (SGLT) 2 inhibitor, against diabetic nephropathy in streptozotocin induced diabetic rats

  2021cites this paper
• Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling.

  2021cites this paper
• Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports

  2021cites this paper
• General Treatment of Heart Failure With Preserved Ejection Fraction and Randomized Trials

  2021cites this paper
• Possibilities of cardio- and nephroprotective eff ects of drugs of the SGLT2 inhibitor group

  2021cites this paper
• Bioanalytical method development for momordicinin and its application to long-term pharmacokinetics in diabetic rats

  2021cites this paper
• Renal Tubular Handling of Glucose and Fructose in Health and Disease.

  2021cites this paper
• Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials

  2021cites this paper
• Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta‐analysis based on randomized controlled trials

  2021cites this paper
• Growth hormone directly favors hepatic ketogenesis in persons with prediabetes or type 2 diabetes mellitus treated with empagliflozin

  2021cites this paper
• Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients

  2021cites this paper
• Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization.

  2021cites this paper
• Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open‐label Randomized Single‐dose Two‐sequence, Two‐treatment, Two‐period Crossover Study

  2020cites this paper
• Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus

  2020cites this paper
• Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management

  2020cites this paper
• An evaluation of empagliflozin and it’s applicability to hypertension as a therapeutic option

  2020cites this paper
• SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

  2020cites this paper
• Opportunities of Antidiabetic Drugs in Cardiovascular Medicine

  2020cites this paper
• Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial

  2020cites this paper
• Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes

  2020cites this paper
• A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.

  2020influential citation
• Glucose transporters in the kidney in health and disease

  2020cites this paper
• Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor

  2020cites this paper
• Pharmacokinetics and bioequivalence of a generic empagliflozin tablet versus a brand-named product and the food effects in healthy Chinese subjects

  2020cites this paper
• Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasma.

  2020cites this paper
• Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study

  2020cites this paper
• Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

  2020cites this paper
• A REVIEW ON PHARMACOLOGY AND THERAPEUTIC EFFECTS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

  2020cites this paper
• Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury

  2020cites this paper
• Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure

  2020cites this paper
• Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis

  2020cites this paper
• Long-term effects of empagliflozin on excitation-contraction-coupling in human induced pluripotent stem cell cardiomyocytes

  2020cites this paper
• Sodium–Glucose Cotransporter 2 Inhibitor–Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review

  2020cites this paper
• Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients

  2020cites this paper
• Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes

  2020cites this paper
• Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial

  2020cites this paper
• Stability Indicating, pH and pKa Dependent HPLC–DAD Method for the Simultaneous Determination of Weakly Ionizable Empagliflozin, Dapagliflozin and Canagliflozin in Pharmaceutical Formulations

  2020cites this paper
• The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

  2020cites this paper
• Effect of Insulin on Proximal Tubules Handling of Glucose: A Systematic Review

  2020cites this paper
• Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States

  2020cites this paper
• SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)

  2019cites this paper
• What does sodium‐glucose co‐transporter 1 inhibition add: Prospects for dual inhibition

  2019cites this paper
• Chronic heart failure: advances in pharmacological treatment and future perspectives.

  2019cites this paper
• Mixed-mode solid phase extraction combined with LC-MS/MS for determination of empagliflozin and linagliptin in human plasma

  2019cites this paper